Literature DB >> 22385471

Review article: the iron overload syndromes.

A Siddique1, K V Kowdley.   

Abstract

BACKGROUND: Iron overload syndromes encompass a wide range of hereditary and acquired conditions. Major developments in the field of genetics and the discovery of hepcidin as a central regulator of iron homeostasis have greatly increased our understanding of the pathophysiology of iron overload syndromes. AIM: To review advances in iron regulation and iron overload syndrome with special emphasis on hereditary haemochromatosis, the prototype iron overload syndrome.
METHODS: A PubMed search using words such as 'iron overload', 'hemochromatosis', 'HFE', 'Non-HFE', 'secondary iron overload' was undertaken.
RESULTS: Iron overload is associated with significant morbidity and mortality. Sensitive diagnostic tests and effective therapy are widely available and can prevent complications associated with iron accumulation in end- organs. Therapeutic phlebotomy remains the cornerstone of therapy for removal of excess body iron, but novel therapeutic agents including oral iron chelators have been developed for iron overload associated with anaemia.
CONCLUSIONS: Iron overload disorders are common. Inexpensive screening tests as well as confirmatory diagnostic tests are widely available. Increased awareness of the causes and importance of early diagnosis and knowledge of the appropriate use of genetic testing are encouraged. The availability of novel treatments should increase therapeutic options for patients with iron overload disorders.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22385471     DOI: 10.1111/j.1365-2036.2012.05051.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  31 in total

1.  Simultaneous quantitative susceptibility mapping (QSM) and R2* for high iron concentration quantification with 3D ultrashort echo time sequences: An echo dependence study.

Authors:  Xing Lu; Yajun Ma; Eric Y Chang; Qun He; Adam Searleman; Annette von Drygalski; Jiang Du
Journal:  Magn Reson Med       Date:  2018-01-04       Impact factor: 4.668

Review 2.  Zebrafish models of human liver development and disease.

Authors:  Benjamin J Wilkins; Michael Pack
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

3.  ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.

Authors:  Zhi Liu; Jing Qiao; Tamas Nagy; May P Xiong
Journal:  J Control Release       Date:  2018-05-22       Impact factor: 9.776

4.  Blockade of angiotensin AT1 receptors prevents arterial remodelling and stiffening in iron-overloaded rats.

Authors:  Helbert Gabriel Fidelis; Jandinay Gonzaga Alexandre Mageski; Susana Curry Evangelista Goes; Tatiani Botelho; Vinicius Bermond Marques; Renata Andrade Ávila; Leonardo Dos Santos
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

Review 5.  Targeting iron assimilation to develop new antibacterials.

Authors:  Timothy L Foley; Anton Simeonov
Journal:  Expert Opin Drug Discov       Date:  2012-07-19       Impact factor: 6.098

Review 6.  Iron and infection.

Authors:  Tomas Ganz
Journal:  Int J Hematol       Date:  2017-11-16       Impact factor: 2.490

Review 7.  Recent advances in hemochromatosis: a 2015 update : a summary of proceedings of the 2014 conference held under the auspices of Hemochromatosis Australia.

Authors:  Dilum Ekanayake; Clinton Roddick; Lawrie W Powell
Journal:  Hepatol Int       Date:  2015-03-12       Impact factor: 6.047

8.  Iron overload patients with unknown etiology from national survey in Japan.

Authors:  Katsuya Ikuta; Mayumi Hatayama; Lynda Addo; Yasumichi Toki; Katsunori Sasaki; Yasuaki Tatsumi; Ai Hattori; Ayako Kato; Koichi Kato; Hisao Hayashi; Takahiro Suzuki; Masayoshi Kobune; Miyuki Tsutsui; Akihiko Gotoh; Yasuo Aota; Motoo Matsuura; Yuzuru Hamada; Takahiro Tokuda; Norio Komatsu; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

Review 9.  The tumor suppressor protein p53 and the ferroptosis network.

Authors:  Rui Kang; Guido Kroemer; Daolin Tang
Journal:  Free Radic Biol Med       Date:  2018-05-23       Impact factor: 7.376

10.  Does hemochromatosis predispose to celiac disease? A study of 29,096 celiac disease patients.

Authors:  Jonas F Ludvigsson; Joseph A Murray; Paul C Adams; Maria Elmberg
Journal:  Scand J Gastroenterol       Date:  2012-12-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.